The Cooper Companies, Inc.

The Cooper Companies, Inc.

COO

$60.77

Updated: 03/11/2026, 18:33:21

Market Cap
$11.56B
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US

No historical data available

Company Profile

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.

USD
NASDAQ
CEO: Albert G. White
Employees: 15,000
https://www.coopercos.com
Asset Summaries
Latest generated summaries for COO

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
COO-10-k-fy2025.html1.9 MBtext/htmlENFiled 05/12/2025Period ended 31/10/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 68 KPI observations

Revenue

$4.1B

FY 2025 · Reported

Net income

$0.4B

FY 2025 · Reported

Gross margin

65.5%

FY 2025 · Calculated

Free cash flow

$0.4B

FY 2025 · Calculated

R&D intensity

4.2%

FY 2025 · Calculated

Share repurchases

$0.3B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

MiSight 1 day myopia lens
CooperVision product franchises
Paragard contraceptive IUD
CooperSurgical portfolio
CooperSurgical product additions include donor gametes, Paragard, cord blood/tissue storage
MiSight myopia management expansion

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureAmericas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureAmericas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureAmericas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureAmericas: 41.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureAmericas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureAmericas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)Americas: 41.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureAmericas: 41.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureAmericas: 41.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

Revenue exposure by reported geography
FY 2025 share of total net sales. Regional segments are kept as regions rather than falsely allocated to individual countries.
Americas
+41.0%
EMEA
+38.8%
Asia Pacific
+20.2%

How the business makes money

CooperSurgical segment

CooperSurgical competes in fertility and women's health care: medical devices, cryostorage (cord blood/tissue), contraception, IVF products and services

98%
Source evidence
“Our CooperSurgical business competes in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception.”

CooperVision segment

CooperVision competes in the worldwide contact lens market with spherical, toric, multifocal and toric multifocal lenses using silicone hydrogel Aquaform technology

98%
Source evidence
“We compete in the worldwide contact lens market with our spherical, toric, multifocal and toric multifocal contact lenses offered in materials like silicone hydrogel Aquaform technology.”

Two operating segments

CooperVision and CooperSurgical are the company's two business segments.

95%
Source evidence
“CooperVision and CooperSurgical are encountering consolidation in their customer bases and emergence of more centralized large customer groups and retail chains.”

Two operating segments: CooperVision and CooperSurgical

CooperVision (contact lenses) and CooperSurgical (medical devices, fertility/IVF, Paragard, cord blood/tissue storage)

95%
Source evidence
“CooperVision markets our products through our own field sales representatives, distributors and eye care practitioners”

CooperSurgical customer base

CooperSurgical customers primarily consist of hospitals and surgery centers, OB/GYN medical offices and fertility clinics

95%
Source evidence
“our customers, who primarily consist of hospitals and surgery centers, OB/GYN medical offices and fertility clinics”

CooperVision distribution channels

Field sales reps, distributors, eye care practitioners (optometrists, ophthalmologists, opticians, optical chains), mass merchandisers, plus digital/e-commerce marketing

90%
Source evidence
“CooperVision markets our products through our own field sales representatives, distributors and eye care practitioners, including optometrists, ophthalmologists, opticians and optical chains. CooperVision also sells to distributors and to mass merchandisers who offer eye care services.”

MiSight 1 day myopia lens

MiSight 1 day: first and only FDA-approved lens to slow myopia progression in children (ages 8-12); also NMPA (China) and MHLW (Japan) approved

98%
Source evidence
“CooperVision has FDA approval for its MiSight 1 day lens, which is the first and only FDA-approved product indicated to slow the progression of myopia in children with treatment initiated between the ages of 8-12.”

CooperVision product franchises

Single-use franchises: clariti, MyDay, MyDay Energys; FRP focus: Biofinity and Avaira Vitality; specialty: ActivControl myopia lenses, ortho-k, scleral lenses

97%
Source evidence
“Our single-use silicone hydrogel product franchises, clariti, MyDay and MyDay Energys remain a focus... the Biofinity and Avaira Vitality product families comprise our focus in the FRP, or frequent replacement product, market”

Paragard contraceptive IUD

Paragard contraceptive intrauterine devices drove CooperSurgical office and surgical sales growth in FY2025

95%
Source evidence
“office and surgical net sales increased primarily due to increased sales of Paragard contraceptive intrauterine devices”

CooperSurgical portfolio

CooperSurgical focuses on family and women's health care including fertility, medical devices, cryostorage and contraception.

95%
Source evidence
“CooperSurgical focuses on selected segments of the family and women's health care market with a diversified portfolio of products and services including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception.”

CooperSurgical product additions include donor gametes, Paragard, cord blood/tissue storage

CooperSurgical added donor gametes, Paragard and cord blood and cord tissue storage services, expanding direct-to-consumer awareness campaigns

90%
Source evidence
“Since the addition of donor gametes, Paragard and cord blood and cord tissue storage services, CooperSurgical has also expanded its awareness campaigns to include direct-to-consumer elements”

MiSight myopia management expansion

With the addition of MiSight, CooperVision expanded sales capabilities with myopia management specialists and direct-to-consumer marketing (print, internet/social media, radio, television)

90%
Source evidence
“With the addition of MiSight, CooperVision has expanded the breadth and depth of its sales capabilities by adding myopia management specialists while expanding awareness campaigns to include direct-to-consumer elements”

CooperVision net sales by geography FY2025 vs FY2024

CooperVision FY2025: Americas $1,124.3M (+5%), EMEA $1,064.4M (+8%), Asia Pacific $555.1M (flat)

99%
Source evidence
“Americas$1,124.3 $1,067.3 5 % EMEA1,064.4 988.3 8 % Asia Pacific555.1 553.8 — %”

CooperSurgical net sales by category FY2025 vs FY2024

CooperSurgical FY2025 $1,348.6M (+5%): Office and surgical $824.0M (+6%, driven by Paragard and obp Surgical acquisition), Fertility $524.6M (+3%, genomic and gamete services)

99%
Source evidence
“Office and surgical$824.0 $774.7 6 % Fertility524.6 511.3 3 % $1,348.6 $1,286.0 5 %”

CooperVision net sales by category FY2025 vs FY2024

CooperVision FY2025 net sales $2,743.8M (+5%): Toric/multifocal $1,351.3M (+7%), Sphere/other $1,392.5M (+3%); FX tailwind ~$16.0M

99%
Source evidence
“Toric and multifocal $1,351.3 $1,257.2 7 % Sphere, other 1,392.5 1,352.2 3 % $2,743.8 $2,609.4 5 %”

Operations and dependencies

Silicone hydrogel lens component supply disruption risk

Disruptions in supplies of raw materials, particularly components used to manufacture silicone hydrogel lenses, cited as a significant risk

90%
Source evidence
“Disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses.”

Manufacturing and distribution footprint

Significant manufacturing and distribution sites in North America, Latin America and Europe.

90%
Source evidence
“We have significant manufacturing and distribution sites in North America, Latin America and Europe.”

Positioning and strategy

obp Surgical acquisition

CooperSurgical acquired obp Surgical on August 1, 2024, contributing to office and surgical sales growth

95%
Source evidence
“office and surgical net sales increased primarily due to increased sales of Paragard contraceptive intrauterine devices and the acquisition of obp Surgical on August 1, 2024.”

CooperVision competitive landscape

CooperVision competes with contact lens makers, eyeglass manufacturers and vision correction providers, with rising Asia Pacific entries.

90%
Source evidence
“We cannot be assured that we will not encounter increased competition in the future, for example with increased product entries from Asia Pacific contact lens manufacturers, or that our competitors' newer contact lens products will not successfully erode CooperVision's contact lens business”

R&D expenses and focus FY2025

R&D $172.2M (+11%): CooperVision $91.3M (contact lens and manufacturing technology), CooperSurgical $80.9M (surgical devices, fertility solutions)

97%
Source evidence
“CooperVision$91.3 3 %$82.9 3 %10 % CooperSurgical80.9 6 %72.2 6 %12 % $172.2 4 %$155.1 4 %11 %”

R&D expense growth

Research and development expense $172.2M FY2025, up from $155.1M FY2024 and $137.4M FY2023

97%
Source evidence
“Research and development expense172.2 155.1 137.4”

Risks, financing, and outlook

Gross margin decline FY2025

Consolidated gross margin fell to 66% in FY2025 from 67%, driven by inventory/long-lived asset write-offs and severance from workforce optimization

97%
Source evidence
“Consolidated gross margin decreased in fiscal 2025 to 66% compared to 67% in fiscal 2024, primarily driven by inventory and long-lived asset write-offs and severance costs related to workforce optimization initiatives.”

Interest expense

Interest expense $100.0M FY2025 vs $114.3M FY2024

97%
Source evidence
“Interest expense100.0 114.3 105.3”

Interest expense FY2025

Interest expense $100.0M in FY2025, down 13% from $114.3M on lower rates and average debt balances; FX loss $8.0M on USD movements against intercompany balances

95%
Source evidence
“Interest expense decreased during fiscal 2025 compared to the prior year, primarily due to lower interest rates and lower average debt balances.”

Management outlook and risk environment

Optimistic on long-term contact lens and healthcare markets but flags tariffs, FX, inflation, supply chain, regulatory risks that have adversely affected sales, cash flow and performance in the past

96%
Source evidence
“escalating global trade barriers and disruptions, such as the impact of tariffs. These risks and uncertainties have adversely affected our sales, cash flow and performance in the past”

Auditor tenure and clean opinions

KPMG LLP (auditor since 1982) issued unqualified opinions on financial statements and effective ICFR as of October 31, 2025

98%
Source evidence
“We have served as the Company’s auditor since 1982.”

Stock split adjusted presentation

All periods adjusted for the four-for-one stock split effected February 16, 2024

98%
Source evidence
“All periods presented have been adjusted to reflect the four-for-one stock split effected on February 16, 2024”

EU MDR/IVDR and UK medical device regulation

Subject to EU MDR/IVDR and UK rules; certain IVDs compliant with EU IVDD/IVDR can continue to be placed on the Great Britain market until the sooner of CE certificate expiration or June 30, 2030

90%
Source evidence
“Certain IVDs in compliance with the EU IVDD or the EU IVDR can continue to be placed on the Great Britain market until the sooner of CE certificate expiration or June 30, 2030”

Healthcare reform: ACA, IRA Medicare drug price negotiation, OBBBA

IRA Medicare drug price negotiations expanding: negotiated prices effective 2026, Part D out-of-pocket cap rising to $2,100; OBBBA introduces Medicaid/ACA eligibility changes expected to affect patient access and reimbursement

90%
Source evidence
“Beginning in 2026, negotiated prices for selected high-cost drugs will take effect, and the out-of-pocket cap for Medicare Part D enrollees will rise to $2,100.”

Asia Pacific regulatory complexity: China NMPA and Japan PMD Act

China (NMPA) requires proof of home country approval, in-country type testing and generally in-country clinical trials; Japan (PMD Act/PMDA) regulates contact lenses as Class III devices with lengthy premarket approval

90%
Source evidence
“in China, manufacturers must provide proof of home country approval (such as the United States or EU) as part of the regulatory registration/approval process.”

ESG and environmental regulation compliance exposure

Subject to evolving ESG disclosure and environmental chemical regulations in EU, California, SEC and other jurisdictions.

85%
Source evidence
“the European Union Corporate Sustainability Reporting Directive (CSRD) became effective in 2023 and applies to both EU and non-EU entities.”

Variable rate indebtedness and interest rate exposure

Variable rate indebtedness and associated interest expense impacted by rate increases; acquisition-related leverage and financing access cited as risks

90%
Source evidence
“Our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds.”

Customer consolidation concentration risk

Market consolidation of large customers globally could concentrate a larger proportion of business among fewer customers

90%
Source evidence
“Market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers.”

Tariff and trade barrier risk

Risk of actual imposition or threats of tariffs, customs duties and fees by the U.S. government and other nations, plus retaliatory trade measures and mitigation costs

90%
Source evidence
“The actual imposition or threats of tariffs, customs duties and fees by the U.S. government and other nations in response and other retaliatory actions, such as trade protection measures”

Manufacturing disruption and silicone hydrogel process dependency

Manufactures a significant portion of medical device products sold; silicone hydrogel manufacturing cost-effectiveness is a competitive factor.

90%
Source evidence
“materials such as silicone hydrogel require improvements to our manufacturing processes to make them cost-effective. While we have improved our manufacturing capabilities for our silicone hydrogel products, our failure to continue to develop improvements to our manufacturing processes and reduce our cost of goods could significantly impact our ability to compete.”

Acquisition strategy risks

Growth strategy relies on acquisitions, which involve integration, leverage and goodwill impairment risks.

90%
Source evidence
“As part of our growth strategy, we intend to continue to consider acquiring complementary technologies, products and businesses and establishing joint ventures or other strategic relationships.”

New distribution models threaten contact lens business

Online fulfillment and telemedicine models may conflict with CooperVision's strategy and customer relationships.

90%
Source evidence
“more contact lenses are being fulfilled directly to the consumer by manufacturers and wholesalers via online platforms, telemedicine is gaining popularity and more vision correction prescriptions are being provided through online refractive exams rather than in office by an eye care practitioner.”

Trade sanctions and tariff exposure

Changes in import/export policies and tariffs may disrupt supply chain and impact competitiveness.

90%
Source evidence
“Changes in import and export policies, including new, increased or retaliatory tariffs, sanctions and countersanctions and customs restrictions by the U.S. and foreign governments, may disrupt our supply chain, adversely affect our relationships with customers and impact our competitiveness.”

Inflation risk on pricing

Higher inflation may increase costs and may not be fully offset by price increases.

90%
Source evidence
“In a higher inflationary environment, we may be unable to raise the prices of our products and services sufficiently to keep up with the rate of inflation.”

Technological substitution risk (e.g., Lasik)

Lasik and new pharmaceutical products may decrease demand for optical products.

90%
Source evidence
“corneal refractive surgical procedures such as Lasik surgery and the development of new pharmaceutical products may decrease the demand for our optical products.”

Macroeconomic and recessionary pressures

Inflation, recession, labor costs and currency fluctuations have adversely affected manufacturing costs and revenues.

90%
Source evidence
“Our global business has been negatively affected by local economic conditions, including inflation, increasing labor costs, recession, and currency exchange rate fluctuations, which has adversely affected our cost to manufacture and provide our products and services and revenues generated through sales of such products and services.”

Acquisition integration and fair value measurement risks

Acquisition-related risks include integration failures, measurement-period fair value adjustments to acquired assets/liabilities, delayed regulatory approvals, and increased leverage

90%
Source evidence
“the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period”

Reimbursement and coverage risk for CooperSurgical products

Sales depend on payor coverage and adequacy of reimbursement; reimbursement may be reduced, eliminated, or coverage denied, and even perceived changes can cause demand volatility

90%
Source evidence
“Even the perception of potential changes in coverage—such as proposed rulemaking, draft guidance, or litigation affecting reimbursement frameworks—can lead to volatility in demand, as providers and patients may delay or avoid use of our products”

Material exposure graph

MiSight 1 day
Demand Driver

MiSight drove CooperVision sphere/other category growth; regulatory approvals in FDA, NMPA and MHLW jurisdictions support myopia management expansion

Relevance 88·Dependency 55·Confidence 95
Source evidence
“Sphere, other grew primarily through MiSight and MyDay, offset by a decrease in legacy hydrogel products.”
silicone hydrogel lens components
Supplier Dependency

Sole-source suppliers for silicone hydrogel lens components create supply disruption risk; mitigated by contracts and safety stocks but alternative supplier switching on short notice could disrupt product supply.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“if current raw material suppliers fail to supply sufficient materials on a timely basis, or at all for any reason, we could experience inventory shortages and disruption in the supply of products”
contact lens wearers
Demand Driver

Growth tied to lower wearer dropout rates via improved designs/materials and shift toward single-use and monthly modalities

Relevance 80·Dependency 70·Confidence 90
Source evidence
“We believe that there will be lower contact lens wearer dropout rates as technology improves and enhances the wearing experience through a combination of improved designs and materials and the growth of preferred modalities such as single-use and monthly wearing options.”
Global and regional key account customers
Customer Exposure

Customer consolidation means key accounts represent a larger share of revenue; disruption to these relationships would materially harm the business.

Relevance 80·Dependency 65·Confidence 90
Source evidence
“global and regional key account customers now represent a larger proportion or concentration of our business and any disruption to these relationships may have a material adverse impact on our business.”
hospitals, surgery centers, OB/GYN offices, fertility clinics
Revenue Exposure

CooperSurgical revenue depends on hospitals, surgery centers, OB/GYN offices and fertility clinics, whose purchasing depends on payor coverage and reimbursement.

Relevance 80·Dependency 65·Confidence 90
Source evidence
“Market acceptance and sales of our CooperSurgical products to our customers, who primarily consist of hospitals and surgery centers, OB/GYN medical offices and fertility clinics, will depend on the availability of payor coverage”
Silicone hydrogel
Raw Material Dependency

Silicone hydrogel contact lens manufacturing requires continued process improvements to remain cost-effective and competitive.

Relevance 75·Dependency 70·Confidence 90
Source evidence
“materials such as silicone hydrogel require improvements to our manufacturing processes to make them cost-effective.”
International operations / currency fluctuations
Currency Exposure

Approximately half of net sales are generated outside the US, exposing results to currency exchange rate fluctuations.

Relevance 75·Dependency 70·Confidence 90
Source evidence
“fluctuations in currency exchange rates adversely affecting our results;”
Inflation
Revenue Exposure

Inflation raises manufacturing costs and may not be offset by price increases; macro weakness can reduce customer purchases.

Relevance 75·Dependency 60·Confidence 85
Source evidence
“Our global business has been negatively affected by local economic conditions, including inflation, increasing labor costs, recession, and currency exchange rate fluctuations”
EU MDR/IVDR
Regulatory Exposure

New or changed medical device regulations including EU MDR/IVDR affect Cooper's operations in the contact lens and medical device industries; cited as a significant risk.

Relevance 75·Dependency 60·Confidence 90
Source evidence
“including but not limited to the EU Medical Devices Regulation (MDR) and the EU In Vitro Diagnostic Medical Devices Regulation (IVDR).”
Paragard IUD
Revenue Exposure

Paragard contraceptive IUD sales were a primary driver of CooperSurgical office and surgical revenue growth in FY2025

Relevance 75·Dependency 40·Confidence 93
Source evidence
“office and surgical net sales increased primarily due to increased sales of Paragard contraceptive intrauterine devices”
tariffs
Geopolitical Exposure

Company explicitly cites escalating global trade barriers and tariffs as risks that have adversely affected and could further affect sales, cash flow and performance

Relevance 72·Dependency 40·Confidence 90
Source evidence
“escalating global trade barriers and disruptions, such as the impact of tariffs. These risks and uncertainties have adversely affected our sales, cash flow and performance in the past”
Tariffs and trade sanctions
Geopolitical Exposure

New or retaliatory tariffs and sanctions may disrupt supply chain, customer relationships and competitiveness.

Relevance 70·Dependency 55·Confidence 85
Source evidence
“Changes in import and export policies, including new, increased or retaliatory tariffs, sanctions and countersanctions and customs restrictions by the U.S. and foreign governments, may disrupt our supply chain”
tariffs and trade barriers
Cost Driver

Tariffs, customs duties and retaliatory trade measures raise costs and could disrupt supply of product to or through affected countries; mitigation efforts themselves carry impact.

Relevance 70·Dependency 50·Confidence 85
Source evidence
“as well as the impact of the Company’s efforts to mitigate the effects of such tariffs or similar measures.”
US healthcare reform (IRA, OBBBA)
Regulatory Exposure

IRA Medicare price negotiations and OBBBA Medicaid/ACA changes exert downward pricing pressure and may reduce patient access and demand for Cooper products.

Relevance 70·Dependency 50·Confidence 85
Source evidence
“These changes may affect patient access to care and alter the reimbursement environment for providers and manufacturers.”
USD
Currency Exposure

Foreign exchange movements materially affect reported sales and earnings; FX added ~$16.0M to CooperVision sales and caused an $8.0M intercompany FX loss

Relevance 70·Dependency 45·Confidence 90
Source evidence
“the growth experienced across all categories was positively impacted by favorable foreign exchange rate fluctuations of approximately $16.0 million.”
EMEA
Revenue Exposure

EMEA was CooperVision's fastest-growing region at $1,064.4M (+8%), helped by favorable FX; combined with Americas it represents the majority of contact lens revenue

Relevance 68·Dependency 39·Confidence 95
Source evidence
“The growth in EMEA was positively impacted by favorable foreign exchange rate fluctuations.”
Online / direct-to-consumer distribution models
Competitive Exposure

Internet-driven fulfillment and telemedicine models may interfere with CooperVision's customer relationships and strategy.

Relevance 65·Dependency 50·Confidence 85
Source evidence
“CooperVision's failure to adapt to the threats posed by these new and emerging distribution models and Internet driven services may have a material adverse impact on our business.”
third-party payor coverage and reimbursement
Revenue Exposure

Reimbursement levels may be reduced or eliminated and coverage denied based on clinical guidelines or cost-effectiveness assessments, with even perceived changes causing demand volatility.

Relevance 65·Dependency 50·Confidence 85
Source evidence
“Reimbursement levels may be reduced or eliminated altogether, and coverage may be denied or restricted based on clinical guidelines, cost-effectiveness assessments, or changes in regulatory classification.”
large consolidating customers
Customer Exposure

M&A-driven consolidation of large customers globally increases revenue concentration and customer bargaining power.

Relevance 60·Dependency 55·Confidence 85
Source evidence
“Market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers.”
Interest expense / financing costs
Cost Driver

The Company carries material debt service costs, with interest expense of $100.0M in FY2025, down from $114.3M in FY2024.

Relevance 55·Dependency 50·Confidence 90
Source evidence
“Interest expense100.0 114.3 105.3”
Corneal refractive surgery (Lasik)
Technology Dependency

Lasik and new pharmaceuticals could substitute for contact lenses and reduce demand for optical products.

Relevance 55·Dependency 40·Confidence 85
Source evidence
“corneal refractive surgical procedures such as Lasik surgery and the development of new pharmaceutical products may decrease the demand for our optical products.”
EU Corporate Sustainability Reporting Directive (CSRD)
Regulatory Exposure

Evolving ESG disclosure regimes (CSRD, California climate rules, SEC climate rule) impose compliance cost and litigation risk.

Relevance 50·Dependency 40·Confidence 80
Source evidence
“the European Union Corporate Sustainability Reporting Directive (CSRD) became effective in 2023 and applies to both EU and non-EU entities.”
Full company information
Latest profile, trading, valuation, and identifier data stored for COO.
Share price
$60.77
Market cap
$11.56B
Exchange
NASDAQ
Currency
USD
CEO
Albert G. White
Employees
15,000
IPO date
21/01/1983
Beta
0.825
Last dividend
$0.00
Day range
$60.22 – $61.23
52-week range
$51.01 – $89.83
1-day performance
-0.86%
1-year performance
19.13%
Current drawdown (1Y)
-32.35%
CIK
0000711404
CUSIP
216648501
ISIN
US2166485019
Created
07/12/2025, 03:24:52
Last update
03/11/2026, 18:33:21

Track The Cooper Companies, Inc. with an AI analyst

See which prediction-market events move COO, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to COO from your Railway `news_articles` table.